Omnicare — Investor Presentation (March 2012)
19 slides from Omnicare's investor presentation, Mar 6, 2012
Slide 1: March 6, 2012
March 6, 2012
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward-looking Statements Cx . the F ‘Securities Litigation Reform Act of 1995. These forward-looking a fof or ‘ k uncertainties i th i iffer materially The most significant is intie mpany m 10-K, Form 10-Q and Form 8-K -_ iS Commission. 6 redictic y differ materially. as
Slide 3: Value Creation
Value Creation
Slide 4: Sizing Up the Business
Sizing Up the Business (in $ mitions) 2011 2011 Revenue: Adjusted Operating Income") 1 € Pa) Long-Term Care Group Specialty Care Grouy Other/Corporate (Includes Interest Expense) Excudes special tems. Financial internation’ om the vests page
Slide 5: Transitioning to an Operations-Driven Company
Transitioning to an Operations-Driven Company Focus on Three Core Operating Objectives Establish organic growth within our Long-Term Care Group Create more standardization across the company Reposition Specialty Care Group for an elevated level of growth
Slide 6: Establish Organic Growth within LTC
Transitioning to an Operations-Driven Company Establish Organic Growth within LTC Quarterly Net Organic Bed Gain/Loss 2011 vs. 2010 8,000 (8,000) (16,000) (24,000) S6.6xbetter Byes] thanz010 2 a Q 2010 Net Organic Bed Gain/Loss 42011 Net Organic Bed Gain/Loss
Slide 7: Creating More Standardization
Transitioning to an Operations-Driven Company Creating More Standardization * Operating efficiencies — Benchmarking — Insourcing — Six Sigma-Focused Culture Technological improvements — Automation ALV/ULV Estimated Script Volume as % of Omnicare’s Long-Term Care Scripts 71.2% 63.4% — Customer-facing
Slide 8: Omnicare's secure web-based worksite for customers
Omnicare’s secure web-based worksite for customer ; and
Slide 9: Specialty Drug Market Characteristics
Specialty Drug Market Characteristics Unique Solutions to Complex Disease States Specialty product characteristics 2010 FDA Approvals — Annual cost of therapy ($25,000 40 to $150,000 per year) 30 | — Patient population (ranging from a hundreds to 250,000) 0 — Route of administration New Products New
Slide 10: Specialty Care Group
Specialty Care Group Business Model, Economics Vary Depending Upon Operational Platform Brand Supply Patient Support Chain Services Solutions Specialty End of Life Care Support Pharmacy Services Customer Third Party Payers Revenue Fee for Service Model Per Diem del Product Manufacturer owns the prod
Slide 11: Repositioning Specialty Care Group for Elevated Growth
Transitioning to an Operations-Driven Company Repositioning Specialty Care Group for Elevated Growth Omnicare specialty care growth has been robust. ..and opportunities exist to further accelerate growth through: * Continued improvements to the organizational structure - made in ale: izatic — Platfo
Slide 12: Compelling Avenues for Growth
Compelling Avenues for Growth Organic Growth New Therapeutic Categories Industry New Growth Operating Rates Platforms Adjacent Aging Markets Population
Slide 13: Fourth Quarter 2011 Highlights
Fourth Quarter 2011 Highlights Gross profit increased 3.9% sequentially to $359.7M on 0.8% increase in sales — Gross margin sequentially higher by 69 bps to 23.1%, reflecting a higher generic dispensing rate Adjusted EBITDA") increased 3.6% sequentially to $162.9M Adjusted EPS") of $0.58 vs. $0.54 i
Slide 14: Focus on Cash Flow
Focus on Cash Flow Significant Amount of Earnings Converted into Cash Flow Adjusted EBITDA from Continuing Operations vs. Cash Flows (3) (in $ millions) 2009 2010 2011 S EBITDA “CFFO &FCF Data fom te iestos’ page 2, aloes discontinued operations rotrtet equi website under Suplemental Financia Dat’ f
Slide 15: Cash flow generation is expected to be redeployed toward growth drivers
> Cash flow generation is expected to be redeployed toward growth drivers
Slide 16: Capital Allocation
Capital Allocation Putting Significant Cash Flows to Work Capital R (in millions, except %s) 2009 lm Dividends Paid 2010 iam YTD Share Repurchases 2011 O=% Returned
Slide 17: Longer-Term Targets
Longer-Term Targets “) es + Adjusted Diluted EPS (old methodology) pienaicrelgh eugene. three) years + Cash Flow from Operations $400-$500 million annually + Capital Returned to Shareholders Approximately 25% per year?) Focus on continued debt reduction, * Capital Structure management of maturity sc
Slide 18: Value Creation
Value Creation
Slide 19: March 6, 2012
March 6, 2012